Suchergebnisse - "Mikus, Gerd"

PubPharm (599)

81

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications

enthalten in: Archives of toxicology | 2021

von Mueller-Schoell, A. | Michelet, R. | Weinelt, F. | +2

82

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications

enthalten in: Archives of toxicology | 2021

von Mueller-Schoell, A. | Michelet, R. | Weinelt, F. | +2

83

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications

enthalten in: Archives of toxicology | 2021

von Mueller-Schoell, A. | Michelet, R. | Weinelt, F. | +2

84

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups

enthalten in: Cancers | 2021

von Mueller-Schoell, A. | Michelet, R. | Klopp-Schulze, L. | +7

85

How to Interpret an Investigator's Brochure for Meaningful Risk Assessment : Results of an AGAH Discussion Forum

enthalten in: Therapeutic innovation & regulatory science | 2021

von Rengelshausen, J. | Breithaupt-Groegler, K. | Donath, F. | +6

86

Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time

enthalten in: Journal of clinical pharmacology | 2021

von Grass, J. | Rose, P. | Burhenne, J. | +3

87

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

enthalten in: Clinical and translational science | 2021

von Hohmann, N. | Bozorgmehr, F. | Christopoulos, P. | +5

88

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2021

von Mueller-Schoell, A. | Klopp-Schulze, L. | Michelet, R. | +7

89

How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

enthalten in: Therapeutic innovation & regulatory science | 2021

von Rengelshausen, J. | Breithaupt-Groegler, K. | Donath, F. | +6

90

How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum

enthalten in: Therapeutic innovation & regulatory science | 2021

von Rengelshausen, J. | Breithaupt-Groegler, K. | Donath, F. | +6